Research ArticleAsthma

Transgelin-2 as a therapeutic target for asthmatic pulmonary resistance

See allHide authors and affiliations

Science Translational Medicine  07 Feb 2018:
Vol. 10, Issue 427, eaam8604
DOI: 10.1126/scitranslmed.aam8604

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Tickling transgelin-2 for asthma relief

Asthmatics can be refractive to β2-agonists, creating a need for new pathways to be targeted in this disease. Yin et al. discovered that the protein metallothionein-2 was able to reduce airway resistance in rodent asthma models. This improvement was mediated through transgelin-2, and they further studied a transgelin-2 agonist as a new asthma therapeutic. The agonist improved airway function in multiple preclinical asthma models and relaxed human airway smooth muscle cells. These data indicate that activating transgelin-2 for asthma treatment may be more effective than targeting β2-adrenoceptors.